Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hair Loss/Baldness Clear all
Completed Not applicable Interventional Results available

STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia

NCT02503852
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
Puregraft System, Celution System, Kerastem Therapy, Liposuction
Device · Procedure
Lead sponsor
Kerastem Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Highland Park, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 1, 2026, 9:06 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

NCT06018428
View directory record Official record
Conditions
Alopecia Areata
Interventions
bempikibart (ADX-914)
Drug
Lead sponsor
Q32 Bio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 1, 2026, 9:06 PM EDT
Withdrawn Early Phase 1 Interventional

Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

NCT05416320
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia
Interventions
Calcipotriol, Subject's already prescribed drug
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 1, 2026, 9:06 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy Evaluation of the Mosaic Ultra Device

NCT06117293
View directory record Official record
Conditions
Skin Texture Disorder, Photoaging, Wrinkle, Scar, Stretch Mark, Acne Vulgaris, Hair Loss
Interventions
Mosaic
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Lincolnshire, Illinois • Billerica, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 1, 2026, 9:06 PM EDT
Not listed Phase 2 Interventional

Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

NCT05865041
View directory record Official record
Conditions
Alopecia Areata
Interventions
Farudodstat, Placebo
Drug
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Birmingham, Alabama • Fountain Valley, California • Santa Ana, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 1, 2026, 9:06 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of VDPHL01 in Males With AGA

NCT06972264
View directory record Official record
Conditions
Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions
VDPHL01, Placebo
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 1, 2026, 9:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss

NCT00151515
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
minoxidil
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
15 Years to 49 Years · Male only
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Vallejo, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 1, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

NCT01325337
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 5% solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 1, 2026, 9:06 PM EDT
Completed Not applicable Interventional Results available

Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients

NCT03289364
View directory record Official record
Conditions
Breast Cancer
Interventions
Penguin Cold Caps
Device
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 1, 2026, 9:06 PM EDT
Recruiting Phase 2 Interventional

A Study of LAD603 in Adults With Alopecia Areata

NCT07311564
View directory record Official record
Conditions
Alopecia Areata
Interventions
LAD603, Placebo
Drug · Other
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 1, 2026, 9:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Androgenetic Alopecia in Males

NCT00947505
View directory record Official record
Conditions
Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
Interventions
HairMax LaserComb 2009, 7 Beam, HairMax LaserComb
Device
Lead sponsor
Lexington International, LLC
Industry
Eligibility
25 Years to 60 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Palm Beach, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 1, 2026, 9:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair

NCT04048031
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol Supplement Capsules, Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 1, 2026, 9:06 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

NCT01023841
View directory record Official record
Conditions
Eyelash Hypotrichosis, Alopecia Areata
Interventions
bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 1, 2026, 9:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Androgenetic Alopecia in Females, 9 Beam

NCT00981461
View directory record Official record
Conditions
Androgenetic Alopecia, Hair Loss, Female Pattern Baldness
Interventions
HairMax LaserComb, Control Device
Device
Lead sponsor
Lexington International, LLC
Industry
Eligibility
25 Years to 60 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Miami, Florida • Palm Beach, Florida • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 1, 2026, 9:06 PM EDT
Enrolling by invitation Not applicable Interventional

Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair

NCT07221773
View directory record Official record
Conditions
Hair Thinning
Interventions
XVIE
Other
Lead sponsor
Restore Biologics Holdings, Inc. dba Xtressé
Industry
Eligibility
28 Years to 65 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Maitland, Florida • Marriottsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 1, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Results available

Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

NCT03551821
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
ATI-50002
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 1, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)

NCT01451190
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
9
States / cities
Tucson, Arizona • Los Angeles, California • Santa Rosa, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 1, 2026, 9:06 PM EDT
Active, not recruiting Not applicable Interventional

Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients

NCT04180579
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
PAXMAN Scalp Cooler
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 1, 2026, 9:06 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss

NCT03662854
View directory record Official record
Conditions
Alopecia
Interventions
Hair Stimulating Complex (HSC), Phosphate Buffered Saline
Biological · Other
Lead sponsor
Histogen
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 1, 2026, 9:06 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

PAI-1 Expression in Non-scarring Hair Loss

NCT02548689
View directory record Official record
Conditions
Androgenetic Alopecia, Telogen Effluvium, Alopecia Areata
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 1, 2026, 9:06 PM EDT
Recruiting Not applicable Interventional

Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss

NCT05484973
View directory record Official record
Conditions
Alopecia, Chemotherapy-induced Alopecia, Hair Loss, Breast Cancer
Interventions
AMMA Portalbe Scalp Cooling System
Device
Lead sponsor
Cooler Heads Care Inc.
Government
Eligibility
21 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Tucson, Arizona • Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 1, 2026, 9:06 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

NCT02553330
View directory record Official record
Conditions
Alopecia Areata
Interventions
Placebo Cream, Ruxolitinib Phosphate Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 1, 2026, 9:06 PM EDT
Not yet recruiting Not applicable Interventional

Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia

NCT07637071
View directory record Official record
Conditions
Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning
Interventions
Xtressé Hair Growth Gummies, Placebo Comparator
Other · Dietary Supplement
Lead sponsor
Restore Biologics Holdings, Inc. dba Xtressé
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Maitland, Florida • Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 1, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

NCT05218642
View directory record Official record
Conditions
Alopecia, Male Pattern Hair Loss
Interventions
KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg, Matching placebo to KX-826
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Fountain Valley, California • Hialeah, Florida • Hialeah Gardens, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 1, 2026, 9:06 PM EDT